famotidine has been researched along with ticlopidine in 20 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (5.00) | 29.6817 |
2010's | 19 (95.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hiraishi, H; Kanke, K; Maeda, M; Sasai, T; Shimada, T | 1 |
Chan, FK; Lam, KF; Lau, YK; Ng, FH; Tunggal, P | 1 |
Chan, K; Chu, WM; Keung, KK; Kng, C; Kwan, A; Lam, KF; Lau, YK; Li, A; Ng, FH; Tunggal, P; Wong, BC | 1 |
Kawamura, A; Noguchi, K; Ohbuchi, M; Usui, T | 1 |
Hashimoto, E; Izuhara, C; Kaneko, S; Takayama, S; Takeuchi, K; Yamada, N; Yamanaka, S | 1 |
Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Sugano, T; Tsukahara, K; Umemura, S; Yano, H | 1 |
Aburadani, I; Inomata, J; Kinoshita, M; Kurokawa, K; Maruyama, M; Nagata, Y; Usuda, K | 1 |
Horiuchi, H | 1 |
Abramowitz, Y; Arbel, Y; Banai, S; Berliner, S; Birati, EY; Deutsch, V; Finkelstein, A; Halkin, A; Herz, I; Keren, G; Kletzel, H | 1 |
Furuta, T; Ichikawa, H; Iwaizumi, M; Miyajima, H; Nishino, M; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Watanabe, H; Yamada, T; Yamade, M | 1 |
Chen, WC; Cheng, JS; Hsu, PI; Kao, SS; Lai, KH; Liu, CP; Tsai, KW; Tsai, TJ; Tsay, FW; Wang, HM; Wu, DC | 1 |
KuliĆska, E; Laudy, AE; Tyski, S | 1 |
Chen, C; Huang, S; Lin, D; Luo, Y; Wu, Y; Yu, W | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
2 review(s) available for famotidine and ticlopidine
Article | Year |
---|---|
[Strategy to manage low dose aspirin-induced gastrointestinal injury].
Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Famotidine; Gastric Mucosa; Humans; Omeprazole; Peptic Ulcer; Platelet Aggregation Inhibitors; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Proton Pump Inhibitors; Ticlopidine | 2011 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 trial(s) available for famotidine and ticlopidine
Article | Year |
---|---|
Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: a double-blind, randomized trial.
Topics: Acute Coronary Syndrome; Anti-Ulcer Agents; Blood Platelets; Clopidogrel; Double-Blind Method; Esomeprazole; Famotidine; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Treatment Outcome | 2011 |
Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction.
Topics: Acute Coronary Syndrome; Aged; Anti-Ulcer Agents; Aspirin; Chi-Square Distribution; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Esomeprazole; Famotidine; Female; Fibrinolytic Agents; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Intestinal Perforation; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Ticlopidine; Treatment Outcome | 2012 |
Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study.
Topics: Acute Coronary Syndrome; Aged; Anti-Ulcer Agents; Aspirin; Blood Platelets; Clopidogrel; Drug Antagonism; Famotidine; Female; Humans; Male; Middle Aged; Myocardial Infarction; Omeprazole; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2012 |
Platelet inhibitory effect of clopidogrel in patients treated with omeprazole, pantoprazole, and famotidine: a prospective, randomized, crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Aspirin; Chi-Square Distribution; Clopidogrel; Cross-Over Studies; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Famotidine; Female; Histamine H2 Antagonists; Humans; Israel; Linear Models; Male; Middle Aged; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Proton Pump Inhibitors; Single-Blind Method; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine.
Topics: Adult; Anti-Ulcer Agents; Asian People; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Famotidine; Female; Gastric Acidity Determination; Gastric Mucosa; Genotype; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Young Adult | 2014 |
Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Atherosclerosis; Clopidogrel; Double-Blind Method; Famotidine; Female; Helicobacter Infections; Histamine H2 Antagonists; Humans; Male; Middle Aged; Peptic Ulcer; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Recurrence; Ticlopidine; Treatment Outcome | 2017 |
12 other study(ies) available for famotidine and ticlopidine
Article | Year |
---|---|
Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4.
Topics: Aryl Hydrocarbon Hydroxylases; Biotransformation; Clopidogrel; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Interactions; Famotidine; Humans; Oxidoreductases, N-Demethylating; Proton Pump Inhibitors; Recombinant Proteins; Ticlopidine | 2012 |
A new model of gastric bleeding induced in rats by aspirin plus clopidogrel under stimulation of acid secretion. Prophylactic effects of antiulcer drugs.
Topics: Animals; Anti-Ulcer Agents; Aspirin; Clopidogrel; Drug Interactions; Famotidine; Gastric Acid; Gastric Mucosa; Gastrointestinal Hemorrhage; Male; Omeprazole; Peroxidase; Rats; Rats, Sprague-Dawley; Stomach Ulcer; Ticlopidine | 2012 |
Impact of proton pump inhibitors or famotidine on the antiplatelet actions during dual-antiplatelet therapy in Japanese patients.
Topics: Aged; Asian People; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Interactions; Famotidine; Female; Histamine H2 Antagonists; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Proton Pump Inhibitors; Ticlopidine | 2013 |
Proton-pump inhibitors could be innocent when used concomitantly with clopidogrel.
Topics: Acute Coronary Syndrome; Anti-Ulcer Agents; Aspirin; Blood Platelets; Clopidogrel; Famotidine; Female; Humans; Male; Omeprazole; Platelet Aggregation Inhibitors; Ticlopidine | 2012 |
The Impact of Efflux Pump Inhibitors on the Activity of Selected Non-Antibiotic Medicinal Products against Gram-Negative Bacteria.
Topics: Acyclovir; Alendronate; Amitriptyline; Anti-Bacterial Agents; Atorvastatin; Dipeptides; Drug Combinations; Drug Resistance, Multiple, Bacterial; Escherichia coli; Famotidine; Genes, MDR; Klebsiella pneumoniae; Magnesium Sulfate; Microbial Sensitivity Tests; Nicergoline; Pseudomonas aeruginosa; Quinolones; Salmonella; Ticlopidine | 2017 |
The effect of esomeprazole vs famotidine on aspirin/clopidogrel dual therapy after percutaneous coronary intervention.
Topics: Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Esomeprazole; Famotidine; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine; Treatment Outcome | 2019 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |